Jim Cramer of CNBC discussed about Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), Thermo Fisher Scientific Inc. (NYSE:TMO) and Citigroup Inc (NYSE:C).
He explained what analysts thought of the stocks. He discussed about Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) and how this Brazilian company can be a profitable investment. Novogratz thinks that there might be a new government formed in Brazil this fall due to the bad situation and this would benefit the business as the new government would be a pro-business one.
“I pressed him for a specific company. I suggested may be Vale, The dirt cheap mineral company that seems to be doing everything right but being held back by the factors in Brazil. He said he didn’t want to be caught up in some iron ore trade, but what he really liked, what he thought could really fly, was Petrobras, PBR” Cramer stated.
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) has gained over 16% this year so far. However it can’t progress too much under the current administration. He said that if a pro-business administration takes over in the future, he sees the stock to gain as much as 50%.
Cramer then discussed Thermo Fisher Scientific Inc. (NYSE:TMO) and he said that both Lee Cooperman and Larry Williams like this stock. This stock gained over 7% this year so far and 35% over the last one year. Williams said that the stock is inexpensive even after performing consistently because its major customer is Federal Government and Thermo Fisher Scientific Inc. (NYSE:TMO) supplies health research equipment. Cramer thinks that it is time to take a look at this stock.
“TMO’s my favorite idea from today’s conference, both because of its timeliness and because of its dual sponsorship” Cramer stated.
He said that Citigroup Inc (NYSE:C) trades below its book value and the stock is held back by the millions of $ of bad loans and bloated staff, failed leadership, government investigation and a lot more. He doesn’t like the stock much, however the recent happenings helped the stock from mortgage issue nearing a favourable deal to a decent results beating market estimates helped the stock.
Disclosure: None
